Form 4: AGIOS CMO Sells Shares Under Pre-Planned 10b5-1

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, sold 200 shares of common stock for $43.81 per share, following an option exercise, as part of a pre-arranged trading plan.

Summary

• Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, Inc. (AGIO), reported transactions on October 30, 2025.
• Exercised options to acquire 200 shares of common stock at an exercise price of $25.01 per share.
• Sold 200 shares of common stock at a price of $43.81 per share.
• Both the option exercise and the subsequent sale were conducted under a Rule 10b5-1 trading plan.
• Following these transactions, Gheuens beneficially owns 61,727 shares of common stock and 28,584 stock options.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While there's a sale, it's pre-planned under a 10b5-1, which mitigates negative sentiment. The insider profited from the option exercise, which is a positive for the individual but neutral for the company's outlook.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information.
• The sale price of $43.81 per share is significantly higher than the option exercise price of $25.01 per share, indicating a profitable transaction for the insider.

Negatives

• A net reduction in direct beneficial ownership of common stock by the Chief Medical Officer, even if minor and pre-planned.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The routine nature of the transaction under a 10b5-1 plan suggests minimal direct impact on shareholder sentiment or company valuation. It is a standard part of executive compensation.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by the Chief Medical Officer, involving the exercise of stock options and subsequent sale of shares under a pre-arranged Rule 10b5-1 trading plan. Such transactions are common for executive compensation and typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The sale is not indicative of a lack of confidence, given the 10b5-1 plan. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Agios Pharmaceuticals, AGIO, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Sarah Gheuens, Chief Medical Officer, Biotechnology, Pharmaceuticals